Hindustan Unilever Ltd (HUL) is funding a research project to understand the immune response to SARS-CoV-2 among vaccinated people and vaccine efficacy among Indians.

The national-level research is being enabled by the office of the principal scientific adviser to the government of India’s programme that will work on collaborations between industry and academia.

HUL will also support additional analytical and data analyses through its R&D scientists to the consortium partners, it said.

• Fadnavis Offers Phased Plan for Mumbai Airport Terminal 1
• TCPL Packaging Enters Battery Separator Film Business
• Waaree Energies Admits US Solar Import Origin Errors
• Cabinet Approves Rs 62,370 Crore Fertiliser Subsidy for Rabi Season
• Cochin Shipyard Bags ₹498.58 Cr INS Betwa Upgrade Contract

“This is a first-of-its-kind national-level multi-centre study on long-term protection and immunogenicity of vaccines, in combination with an understanding of nutritional and ‘skin immunity’ status in the Indian population,” the company said in a statement on Tuesday.

Stock Covered in the news

Hindustan Unilever Ltd (HUL)-View Detailed Analysis